Angiogenic properties of NSC-70 (UKRAIN/NSC-631570)

JOINT EVENT:25^th World Congress on CANCER SCIENCE AND THERAPY & 10^th World Congress on BIOMARKERS & CLINICAL RESEARCH

October 18-20, 2017 Baltimore, USA

Wassil Nowicky

Ukrainian Anti-Cancer Institute, Austria

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

Another important feature of NSC-631570 is the inhibition of the formation of the new blood vessels supplying a tumor. Due to these antiangiogenic properties NSC-631570 administered before surgery brings about better demarcation of the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been confirmed in breast cancer studies [67, 71, 103-106, 140]. In tests in vitro, NSC-631570 inhibited in a dose-dependent manner the proliferation of human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation model [134]. This inhibition of the neoangiogenesis prevents the metastasis formation as well.

Biography :

Wassil Nowicky obtained Diploma and is the Director of â�?�?Nowicky Pharmaâ�? and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to â�?�?Diplomingeniueurâ�? in 1960 which title was nostrificated in Austria in 1975. He is the inventor of the anti-cancer preparation on basis of celandine alkaloids â�?�?NSC-631570â�?.